PAVMED INC.

PAVM

CIK 0001624326 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$52K
↑+420.0% +$42Kvs FY2024 (Q4)
Gross Profit
$0

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Poor
17/100
  • Profitability
    0ROIC -109.5% (10% = solid, 20%+ = moat)
  • Liquidity
    0Current Ratio 0.17 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.00x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +420.0% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -96880.0% · trend -79899.3pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$31K
investment in PP&E
Stock buybacks (TTM)
share count reduction
Stock-based comp (TTM)
$2M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$39M
everything owned
Total liabilities
$17M
everything owed
Stockholders' equity
$34M
shareholder claim

Recent performance · 45 quarters

Revenue↑+420.0% +$42K
$52K
Net Income↓-108.4% -$70M
$-5M
Free Cash Flow↓-115.6% -$104K
$-14K
Operating Margin↓-95717.6pts
-96880.0%

Drill down